-
New drug aimed at treating and preventing Mesothelioma – OSI-930
-
OSI -930 is an orally active inhibitor. It has been designed to target cancer cell proliferation and new blood vessel growth in certain tumours, by inhibiting the receptor, the pathway that is believed to be the single most important mechanism for recruitment of new blood vessels.
Drug researchers, Simcere Pharmaceutical Group, based in China and OSI Pharmaceuticals in the US have agreed to base the research for the Kit Inhibitor in China. The drug has shown positive results in treating various lung cancers and therefore the proposed treatment of Mesothelioma by using this drug is being investigated.
Mesothelioma is a rare form of lung cancer that is mainly caused by exposure to asbestos. The asbestos fibres when breathed in are lodged in the membrane lining of the lungs and other organs. Over the course of many years the fibres interfere with the cells development which then leads to the onset of Mesothelioma. Due to the long lag time between exposure and development of Mesothelioma victims often have a very limited life expectancy. This is mainly due to the location of the cancer on the surface of the lung and the fact that it does not respond very well to chemotherapy.
Phase 1 which was carried out on healthy volunteers has been completed and Phase 1 being carried out on cancer patients is currently ongoing. Should the drug prove to be successful those suffering from the fatal disease could face a new outlook in the treatment available.
If you have been exposed to asbestos through no fault of your own you could be entitled to compensation. Give our asbestos helpline a call now on 0800 634 1626 to find our more or simply send us your enquiry via email using our online form and we will get in touch with you.
Useful info:
-
Emma Costin
-
01/12/2009
Disclaimer: No information on this website shall be construed as
legal advice and information is offered for general information purposes only based on the current law when the information was first displayed on this website. You should
always seek advice from an appropriately qualified solicitor on any specific legal
enquiry. Calls to or from our legal helpline may be recorded for training and monitoring purposes.
External links are provided for your convenience, but they are beyond the control
of Simpson Millar LLP and no representation is made as to their content. Use or
reliance on any external links and the content thereon provided is at your own risk.
Full terms of use...